You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 23, 2019

Vietnam Investment Review: CPTPP Obligations Alter Vietnam’s IP Landscape

Vietnam Investment Review (VIR)

Due to significant changes to the intellectual property (IP) landscape, the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) indeed poses major challenges to Vietnam in implementing its obligations. Most of the obligations aim to enhance protection for IP proprietors. This will have a particular impact on the life science sectors, benefitting foreign pharmaceutical and agrochemical companies but reducing opportunities, at least in the short-term, for Vietnamese companies.

The obligations under the CPTPP are widespread. The IP chapter of the agreement is the only chapter with obligations affecting both CPTPP members and other member countries of the World Trade Organization. Non-bloc countries with strong IP-based economies such as the EU and the US still enjoy protection at the same level as other CPTPP members.

Vietnam is turning to Industry 4.0 to drive the economy forward, and some Vietnamese companies are now developing IP-oriented products. Thus, as IP serves as an engine for the economy, Vietnam should make the most of the opportunity the CPTPP affords across various areas, including those set out below.

Enforcement

Under the CPTPP, Vietnam must boost the effectiveness of its fight against IP infringement. To this end, Vietnam must assume responsibility for making the enforcement system more transparent and equitable, guaranteeing public access to all its rulings. More significantly, Vietnam must additionally criminalise some IP offenses such as wilful import or export of counterfeit trademark goods or pirated copyright goods, wilful import and domestic use of counterfeit labels or packaging, recording, and trade secret infringement.

Pursuant to a resolution of the National Assembly, Vietnam will amend the prevailing Penal Code in the next three years to codify these crimes. Vietnam would also leave out the requirement for a complaint from the IP owner to take criminal action against counterfeiting.

Regarding border control, the CPTPP requires that a right holder be provided with specific information about a shipment at issue. The CPTPP also allows an ex officio seizure of counterfeits in transit, in a two-year transition, and exports in a three-year transition.

This regulation clears up the doubt whether export of goods could constitute IP infringement. The regulation will also nullify the current relevant provision of the Law on Customs, which spares goods in transit from sanctions.

The pact also requires Vietnam to either pinpoint statutory damages or provide for punitive damages. Currently, no punitive damages are available in Vietnam. As to statutory damages, Article 205.1(c) of the Law on Intellectual Property allows the plaintiff to claim damages, which are capped at VND500 million ($21,739). However, to this end, in addition to the rationale for the claim, the plaintiff must prove that it cannot establish the actual damages. Thus, in fact, this provision has never been effective in practice, and on balance of convenience, courts often refuse to apply the provision.

Trademarks

Under the CPTPP, within three years, Vietnam must set up a mechanism to register sound trademarks, and do its best to register scent trademarks. Currently, the country only protects visible trademarks.

The country must also revisit its approach in recognising the well-known status of a trademark. Currently, authorities acknowledge the well-known status of a mark only if the mark acquires a very high degree of public knowledge from almost every walk of life, a practice that conflicts with the commitments in the CPTPP.

Licence Recordal

The CPTPP eliminates the requirement for registering a trademark licence to establish the validity of such licence against a third party. The draft bill emphasises this elimination, and also sets out that the use of the trademark by the licencee would inure to the benefit of the trademark owner. However, the bill does not specify whether the use of the trademark by companies economically related to the trademark owner, such as affiliates and subsidiaries, also amounts to authorised use.

Licences for other registered IP such as patents still need to be registered to be enforceable against a third party. This presents hurdles to business transactions due to the vague definition of the term “third party”. Any entity other than the signatories, including banks and tax authorities, can claim to be the third party to such license agreement, which may complicate the performance of obligations under unregistered licences.

Domain Name Disputes

Currently, domain name dispute resolution is itself a matter of dispute between duelling authorities. The Ministry of Science and Technology, which administers IP matters, and the Ministry of Information and Communication (MIC), which administers internet matters, have thus far been unable to reach an agreement to set up effective regimes for resolving disputes involving country code top-level domains.

The CPTPP requires Vietnam to set up such a regime. In line with this provision, the National Assembly passed a resolution to require an amendment to Article 130.1(d) on cybersquatting of the Law on Intellectual Property. However, the draft bill does not set out the amendment. Rather, the Ministry of Industry and Trade, which took charge of drafting the bill, recommended the MIC revise the relevant provisions in Decree No.72/2013/ND-CP to reflect the CPTPP’s requirement.

It seems that the battle of domain name disputes between the two ministries still lingers.

Other IP Subject Matters

The CPTPP significantly expands the grace period for patent novelty, from six months to 12 months. Vietnam will need to extend the exceptions for determining novelty when assessing the patentability of an invention. The agreement also alludes to protection of geographical indications, especially in connection with trademarks, and affords protection to the translation or transliteration of geographical indications.

Commitments to Specific Industries

In the agrochemical industry, Vietnam must ensure data exclusivity for undisclosed clinical trial data or other data for agricultural products for 10 years.

Particularly, Vietnam’s regulatory agency must not grant marketing approval to unauthorised parties, for example generic manufacturers, based on data concerning the safety and efficacy of an approved product that has been submitted by other parties in either Vietnam or in other countries. Vietnam has a 10-year transition period to implement this obligation.

In the pharmaceutical sector, Vietnam must also establish a patent linkage system in connection with the marketing approval process.

Balance of Enforcement

The CPTPP seems to create more balanced treatment for entities accused of IP infringement. When the court does not find infringement, the court can award the defendant reasonable legal fees that it spends for the suit. Under the prevailing Law on Intellectual Property, only the plaintiff is entitled to such legal fee award.

In addition, the pact also allows Vietnam to punish the abuse of IP rights by the owner. The draft bill supplements Article 198 of the prevailing Law on Intellectual Property to lay down such regulation. However, the supplemented article does not go into detail about how to determine the abuse.

RELATED INSIGHTS​ 

January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
January 6, 2026
On December 30, 2025, Thailand’s Electronic Transactions Development Agency (ETDA) notified digital marketplace operators of a consolidated list of “high‑risk products” that are subject to strict monitoring on digital platforms. The list was jointly prepared by the Thai Industrial Standards Institute (TISI) and the Food and Drug Administration (FDA) to guide platform compliance in the initial phase of implementation of the Electronic Transaction Committee’s Notification on Other Measures for Marketplace for Goods with Specific Characteristics under Section 18(2) of the 2022 Royal Decree on Digital Platform Businesses Requiring Notification B.E.2568 (2025). The notice is addressed to operators of digital platform services that function as product marketplaces with specific characteristics laid out in the notification. The ETDA states that the TISI and the FDA are closely monitoring the high‑risk product categories on digital platforms, and the published list serves as the baseline reference for platform screening during the initial phase of the notification’s implementation. High‑Risk Product List The list aggregates categories of products that are illegal to sell online or are otherwise tightly regulated under Thai law, with an emphasis on health-related products, controlled substances, medical devices, and a wide range of industrial products that require certification or compliance with specified Thai Industrial Standards, as detailed below. Prohibited and tightly controlled health products. This includes all categories of modern medicines subject to control other than general household remedies; all categories of controlled herbal products except for over-the-counter herbal products; narcotics; psychotropic substances; and medical devices requiring use in medical facilities or a physician’s prescription. Selected industrial products requiring heightened controls. The list highlights dozens of TISI-regulated items commonly sold online. Examples include pacifiers, rice cookers, electrical wire, food wrap film, crayons, washing machines and dryers, air conditioners, electric cookers and air fryers, water heaters, microwave ovens, LED luminaires, hair dryers
January 5, 2026
On December 31, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 57/2025/TT-BYT providing guidance on the classification of medical devices according to technical standards and quality requirements (Circular 57), applicable to procurement activities for medical devices in Vietnam. According to the MOH, the purpose of the classification is to establish a principle-based legal framework and regulations that enable purchasers to easily identify groups of medical devices aligned with their professional requirements and financial capacity. Some of the key stipulations of Circular 57 are outlined below. Basis for Determining Technical Standards and Quality Under Circular 57, the technical standards of medical devices are determined in accordance with Vietnamese laws on standards and technical regulations, through the following means: Certification of conformity with standards in accordance with Vietnamese laws on standards and technical regulations; Results of conformity assessment conducted by an internationally recognized conformity assessment organization or a legally established domestic or foreign conformity assessment organization operating in Vietnam; and Documentation evidencing compliance provided by the medical device owner. The quality of medical devices is determined based on whether the device has been approved for circulation by the relevant marketing authority of one or more jurisdictions. Classification of Medical Devices Circular 57 classifies medical devices into six groups (from Group 1 to Group 6) based on technical standards and quality. Medical devices subject to classification must simultaneously meet technical standards and quality requirements in accordance with professional specifications and user needs, and must be lawfully marketed in Vietnam. Medical devices manufactured in Vietnam may participate in all corresponding groups, provided they meet the technical standards required by the user and are lawfully marketed in Vietnam. Outlook Circular No. 57 will take effect on February 15, 2026, while the classification requirements will become effective on January 1, 2027. Holders of medical
December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted